A PLK1 kinase inhibitor enhances the chemosensitivity of cisplatin by inducing pyroptosis in oesophageal squamous cell carcinoma

BACKGROUND: Targeting PLK1 has recently been proven as a viable therapeutic strategy against oesophageal squamous cell carcinom (ESCC). Therefore, this study aimed to explore whether the PLK1 inhibitor BI2536 is able to sensitize ESCC cells to cisplatin (DDP) and determine the underlying mechanisms....

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:EBioMedicine
Autors principals: Wu, Mengjiao, Wang, Yan, Yang, Di, Gong, Ying, Rao, Feng, Liu, Rui, Danna, Yeerken, Li, Jinting, Fan, Jiawen, Chen, Jie, Zhang, Weimin, Zhan, Qimin
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2019
Matèries:
Research paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6442225/
https://ncbi.nlm.nih.gov/pubmed/30876762
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2019.02.012
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars